Prognostic Value of lncRNA H19 in Gastric Cancer: A Systematic Review and Meta-Analysis
- 1Key Laboratory of Microecology-Immune Regulatory Network and Related Diseases, College of Basic Medical, Jiamusi University, Jiamusi 154007, China
Abstract
LncRNA H19 is a crucial regulatory player in GC and could operate as an attractive biomarker for patient prognosis. This meta-analysis aims to gauge the link between lncRNA H19 expression levels and patient prognosis, as well as clinicopathological features. HR and 95%CI were utilized to evaluate the connection between lncRNA H19 expression and prognosis, as well as clinicopathological features in GC patients. Bioinformatics analysis, potential molecular mechanisms and drug therapy involving lncRNA H19 were predicted through databases. The expression of lncRNA H19 in GC cells was verified through qRT-PCR. High expression of lncRNA H19 is correlated with a lower overall survival rate in GC patients, as well as TNM stage, lymph node metastasis and tumor invasion. Bioinformatics analysis confirmed that lncRNA H19 is significantly expressed in GC and related to poor prognosis. Function prediction analyses suggested that lncRNA H19 may contribute to GC progression through ceRNA regulatory networks, TFs, and predicted interactions with RBPs. Nutlin-3, PD-0332991, and Topotecan were predicted as preliminary candidate drugs. LncRNA H19 was confirmed to be highly expressed in GC cells. LncRNA H19 might act as a feasible biomarker for prognostic prediction in GC, warranting further validation in clinical studies.
Related
- Artificial intelligence-based tongue image analysis for non-invasive screening of gastric cancer, precancerous lesions, and related gastrointestinal disorders: a systematic review
- Prognostic value of the neutrophil-to-lymphocyte ratio in patients with colorectal cancer undergoing chemotherapy: a systematic review and meta-analysis
- Diagnostic accuracy of deep learning for microsatellite instability prediction in gastric cancer: A systematic review and meta-analysis
- Systemic immune-inflammation index predicts survival in gastric cancer: a systematic review and meta-analysis
- Sentinel Node Navigation Surgery in Gastric Cancer: A Systematic Review of Diagnostic Test Accuracy and Clinical Outcomes
BibTeX
@article{song2026prognostic,
title = {{Prognostic Value of lncRNA H19 in Gastric Cancer: A Systematic Review and Meta-Analysis}},
author = {Silu Song and Yi Li and Chenxia Gao and Shuai Li and Shaojing Jin and Shuang Liu},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209276},
url = {https://www.mdpi.com/1422-0067/27/20/9276},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Prognostic Value of lncRNA H19 in Gastric Cancer: A Systematic Review and Meta-Analysis
AU - Silu Song
AU - Yi Li
AU - Chenxia Gao
AU - Shuai Li
AU - Shaojing Jin
AU - Shuang Liu
PY - 2026
DA - 2026/10/19
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209276
UR - https://www.mdpi.com/1422-0067/27/20/9276
AB - LncRNA H19 is a crucial regulatory player in GC and could operate as an attractive biomarker for patient prognosis. This meta-analysis aims to gauge the link between lncRNA H19 expression levels and patient prognosis, as well as clinicopathological features. HR and 95%CI were utilized to evaluate the connection between lncRNA H19 expression and prognosis, as well as clinicopathological features in GC patients. Bioinformatics analysis, potential molecular mechanisms and drug therapy involving lncRNA H19 were predicted through databases. The expression of lncRNA H19 in GC cells was verified through qRT-PCR. High expression of lncRNA H19 is correlated with a lower overall survival rate in GC patients, as well as TNM stage, lymph node metastasis and tumor invasion. Bioinformatics analysis confirmed that lncRNA H19 is significantly expressed in GC and related to poor prognosis. Function prediction analyses suggested that lncRNA H19 may contribute to GC progression through ceRNA regulatory networks, TFs, and predicted interactions with RBPs. Nutlin-3, PD-0332991, and Topotecan were predicted as preliminary candidate drugs. LncRNA H19 was confirmed to be highly expressed in GC cells. LncRNA H19 might act as a feasible biomarker for prognostic prediction in GC, warranting further validation in clinical studies.
SN - 1422-0067
ER -